A Prospective Randomised Control Trial To Study Efficacy And Safety Of Thiazide Diuretic In Subjects With Idiopathic Hypoparathyroidism

A Prospective Randomised Control Trial To Study Efficacy And Safety Of Thiazide Diuretic In Subjects With Idiopathic Hypoparathyroidism - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/073037

Enrollment

Registered

2024-08-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E200- Idiopathic hypoparathyroidism Health Condition 2: E200- Idiopathic hypoparathyroidism

Interventions

Intervention1: Drug Hydrochlorothiazide: Initially Patient will be given Hydrochlorothiazide 12.5mg/day and will be evaluated on day 5 and day 8 for serum calcium phosphorous potassium albumin and uri

Eligibility

Inclusion criteria

Inclusion criteria: All patients fulfilling Criteria for diagnosis of hypoparathyroidism Hypocalcemia Hyperphosphatemia Normal serum creatinine level Low or inappropriately normal plasma iPTH at the time of diagnosis.

Exclusion criteria

Exclusion criteria: Chronic Kidney Disease (CKD) Pregnancy and Lactation Adrenal Insufficiency

Design outcomes

Secondary

Measure	Time frame
Change in 24hr urinary calcium, sodium & phosphorous excretion in subjects with idiopathic hypoparathyroidism with hydrochlorothiazide (HCTZ) treatment. Change in Fractional Urinary Calcium Excretion in subjects with idiopathic hypoparathyroidism with hydrochlorothiazide (HCTZ) treatment. Change in bone turnover markers (CTX/P1NP) in subjects with idiopathic hypoparathyroidism with hydrochlorothiazide (HCTZ) treatment. Increase in plasma iPTH in subjects with idiopathic hypoparathyroidism with hydrochlorothiazide (HCTZ) treatment.Timepoint: one month	—

Measure

Time frame

Change in 24hr urinary calcium, sodium & phosphorous excretion in subjects with idiopathic hypoparathyroidism with hydrochlorothiazide (HCTZ) treatment. Change in Fractional Urinary Calcium Excretion in subjects with idiopathic hypoparathyroidism with hydrochlorothiazide (HCTZ) treatment. Change in bone turnover markers (CTX/P1NP) in subjects with idiopathic hypoparathyroidism with hydrochlorothiazide (HCTZ) treatment. Increase in plasma iPTH in subjects with idiopathic hypoparathyroidism with hydrochlorothiazide (HCTZ) treatment.Timepoint: one month

—

Primary

Measure	Time frame
Increase in Serum Calcium after Treatment with hydrochlorothiazide in subjects with idiopathic Hypoparathyroidism.Timepoint: one month	—

Countries

India

Contacts

Public ContactDr Soham Mukherjee

Postgraduate Institute of Medical Education and Research

drsoham.mukherjee@gmail.com9914743222

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026